{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T21:56:43Z","timestamp":1764194203416},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T00:00:00Z","timestamp":1476403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1038\/leu.2016.283","type":"journal-article","created":{"date-parts":[[2016,10,14]],"date-time":"2016-10-14T15:30:08Z","timestamp":1476459008000},"page":"882-888","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations"],"prefix":"10.1038","volume":"31","author":[{"given":"M","family":"Marchetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Barosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Cervantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Birgeg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Griesshammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-J","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Kr\u00f6ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M F","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Barbui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,10,14]]},"reference":[{"key":"BFleu2016283_CR1","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","volume":"15","author":"M Sant","year":"2014","unstructured":"Sant M, Minicozzi P, Mounier M, Anderson LA, Brenner H, Holleczek B et al. EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014; 15: 931\u2013942.","journal-title":"Lancet Oncol"},{"key":"BFleu2016283_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s10198-015-0725-6","volume":"17","author":"FR Lichtenberg","year":"2016","unstructured":"Lichtenberg FR . The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995-2012. Eur J Health Econ 2016; 17: 833\u2013854.","journal-title":"Eur J Health Econ"},{"key":"BFleu2016283_CR3","first-page":"339","volume":"5","author":"FR Lichtenberg","year":"2016","unstructured":"Lichtenberg FR . The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000-2011. Int J Health Econ Manag 2016; 5: 339\u2013359.","journal-title":"Int J Health Econ Manag"},{"key":"BFleu2016283_CR4","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787\u2013798.","journal-title":"N Engl J Med"},{"key":"BFleu2016283_CR5","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2013807.","journal-title":"N Engl J Med"},{"key":"BFleu2016283_CR6","first-page":"CD010298","volume":"4","author":"AJ Mart\u00ed-Carvajal","year":"2015","unstructured":"Mart\u00ed-Carvajal AJ, Anand V, Sol\u00e0 I . Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev 2015; 4: CD010298.","journal-title":"Cochrane Database Syst Rev"},{"key":"BFleu2016283_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/bjh.12985","volume":"167","author":"JT Reilly","year":"2014","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS et al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol 2014; 167: 418\u2013420.","journal-title":"Br J Haematol"},{"issue":"suppl 5","key":"BFleu2016283_CR8","doi-asserted-by":"publisher","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"A. M. Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015, v85\u2013v99.","journal-title":"Annals of Oncology"},{"key":"BFleu2016283_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/imj.12921","volume":"45","author":"PJ Ho","year":"2015","unstructured":"Ho PJ, Marlton P, Tam C, Stevenson W, Ritchie D, Bird R et al. Practical management of myelofibrosis with ruxolitinib. Intern Med J 2015; 45: 1221\u20131230.","journal-title":"Intern Med J"},{"key":"BFleu2016283_CR10","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","volume":"328","author":"D Atkins","year":"2004","unstructured":"Atkins D, Best D, Briss PA, Eccels M, Falck-Ytter Y, Flottrop S et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490\u20131498.","journal-title":"BMJ"},{"key":"BFleu2016283_CR11","unstructured":"NICE appraisal 2016: (accessed on 25 April 2016) https:\/\/www.nice.org.uk\/guidance\/TA386\/documents\/final-appraisal-determination-document."},{"key":"BFleu2016283_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2648.1994.tb01066.x","volume":"19","author":"PL William","year":"1994","unstructured":"William PL, Webb C . The Delphi technique: a methodological discussion. J Adv Nurs 1994; 19: 180\u2013186.","journal-title":"J Adv Nurs"},{"key":"BFleu2016283_CR13","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L et al. Long-term findings from COMFORT-III, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia 2016; 30: 1701\u20131707.","journal-title":"Leukemia"},{"key":"BFleu2016283_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3324\/haematol.2013.087650","volume":"99","author":"RA Mesa","year":"2014","unstructured":"Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H et al. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 2014; 99: 292\u2013298.","journal-title":"Haematologica"},{"key":"BFleu2016283_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.13379","volume":"170","author":"AJ Mead","year":"2015","unstructured":"Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M et al. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Br J Haematol 2015; 170: 29\u201339.","journal-title":"Br J Haematol"},{"key":"BFleu2016283_CR16","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","volume":"101","author":"Al-AliHaifa Kathrin","year":"2016","unstructured":"Kathrin Al-Ali Haifa, Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafausen P et al. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. Haematologica 2016; 101: 1065\u20131073.","journal-title":"Haematologica"},{"key":"BFleu2016283_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/leu.2015.326","volume":"30","author":"JJ Kiladjian","year":"2016","unstructured":"Kiladjian JJ, Giraudier S, Cassinat B . Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia 2016; 30: 776\u2013781.","journal-title":"Leukemia"},{"key":"BFleu2016283_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/bjh.12459","volume":"162","author":"Ianotto JC1 F Boyer-Perrard","year":"2013","unstructured":"Ianotto JC1 Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL et al. Efficacy and safety of pegylated-interferon a-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol 2013; 162: 783\u2013791.","journal-title":"Br J Haematol"},{"key":"BFleu2016283_CR19","doi-asserted-by":"publisher","first-page":"6669","DOI":"10.1182\/blood-2010-11-320069","volume":"117","author":"RT Silver","year":"2011","unstructured":"Silver RT, Vandris K, Goldman JJ . Recombinant interferon-a may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011; 117: 6669\u20136672.","journal-title":"Blood"},{"key":"BFleu2016283_CR20","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3324\/haematol.2011.061390","volume":"97","author":"K Gowin","year":"2012","unstructured":"Gowin K, Thapaliya P, Samuelsson J, Harrison C, Radia D, Andreasson B et al. Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Haematologica 2012; 97: 1570\u20131573.","journal-title":"Haematologica"},{"key":"BFleu2016283_CR21","unstructured":"Scherber R, Duecka A, Geyer H, Kosiorek H, Kiladjian JJ, Slots S et al. Symptoms, Risk Classification, and Spleen Size in JAK2 Inhibitor-Naive Myelofibrosis: Implications for JAK2 Inhibitor Treatment. E1345. 21st EHA Meeting, 9-12 June 2016 Copenhagen, Denmark, Available at http:\/\/learningcenter.ehaweb.org\/eha\/2016\/21st\/137125\/eha.annual.congress.eha21.abstract.book.html?f=p5m6l12006."},{"key":"BFleu2016283_CR22","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotllib J, Cervantes F, Mesa RA et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015; 100: 1139\u20131145.","journal-title":"Haematologica"},{"key":"BFleu2016283_CR23","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","volume":"120","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Kantarjian HM, Estrov Z, Cortes JA, Thoams DA, Kadia T et al. Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120: 1202\u20131209.","journal-title":"Blood"},{"key":"BFleu2016283_CR24","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","volume":"123","author":"F Passamonti","year":"2014","unstructured":"Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014; 123: 1833\u20131835.","journal-title":"Blood"},{"key":"BFleu2016283_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol 2013; 6: 81.","journal-title":"J Hematol Oncol"},{"key":"BFleu2016283_CR26","doi-asserted-by":"crossref","unstructured":"Griesshammer M, Vannucci AM, Le Coutre P, Tavares RS, Al-Ali HK, Raani P et al Safety and efficacy of ruxolitinib in patients with low platelets enrolled in a phase 3b expanded-access study in myelofibrosis (MF) ASH 2014. Abstract 1859.","DOI":"10.1182\/blood.V124.21.1859.1859"},{"key":"BFleu2016283_CR27","doi-asserted-by":"crossref","unstructured":"Vannucchi AM, Gisslinger H, Harrison CN, Al-Ali HK, Pungolino E, Kiladjiean J-J et al EXPAND: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis (MF) and low platelet counts (50 \u00d7 109\/L to 99 \u00d7 109\/L) at baseline. ASH 2015. Abstract 2817.","DOI":"10.1182\/blood.V126.23.2817.2817"},{"key":"BFleu2016283_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1517\/14740338.2014.916273","volume":"13","author":"S Galli","year":"2014","unstructured":"Galli S, McLornan D, Harrison C . Safety evaluation of ruxolitinib for treating myelofibrosis. Expert Opin Drug Saf 2014; 13: 967\u2013976.","journal-title":"Expert Opin Drug Saf"},{"key":"BFleu2016283_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1586\/17474086.2013.827413","volume":"6","author":"C Harrison","year":"2013","unstructured":"Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J et al. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 2013; 6: 511\u2013523.","journal-title":"Expert Rev Hematol"},{"key":"BFleu2016283_CR30","doi-asserted-by":"crossref","unstructured":"Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M et al Long-term follow-up of a phase 2 study of ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasms, ASH 2015: abstract 2803.","DOI":"10.1182\/blood.V126.23.2803.2803"},{"key":"BFleu2016283_CR31","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1016\/j.thromres.2013.07.014","volume":"132","author":"D Colaizzo","year":"2013","unstructured":"Colaizzo D, Amitrano L, Guardascione MA, Tiscia GL, D'Andrea G, Longo VA et al. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res 2013; 132: e99\u2013e104.","journal-title":"Thromb Res"},{"key":"BFleu2016283_CR32","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","volume":"175","author":"W Ageno","year":"2015","unstructured":"Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an International Registry. JAMA Intern Med 2015; 175: 1474\u20131480.","journal-title":"JAMA Intern Med"},{"key":"BFleu2016283_CR33","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1182\/blood-2012-07-446849","volume":"120","author":"O Benjamini","year":"2012","unstructured":"Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S . Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 2012; 120: 2768\u20132769.","journal-title":"Blood"},{"key":"BFleu2016283_CR34","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, Kantanrjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB18424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117\u20131127.","journal-title":"N Engl J Med"},{"key":"BFleu2016283_CR35","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood.V124.21.1828.1828","volume":"124","author":"S Isfort","year":"2014","unstructured":"Isfort S, Kaifie A, Bennemann K, Jost E, Panse J, Bruemmerndorf TH et al. Comorbidity scales in patients with myeloproliferative neoplasms: which one fits best? Blood 2014; 124: 1828.","journal-title":"Blood"},{"key":"BFleu2016283_CR36","unstructured":"EPAR EMA. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002464\/human_med_001568.jsp&mid=vvv WC0b01ac058001d124. Accessed on 4 July 2016."},{"key":"BFleu2016283_CR37","unstructured":"FDA: ruxolitinib prescribing information www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202192lbl.pdf. Accessed on 4 July 2016."},{"key":"BFleu2016283_CR38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 2013; 122: 1395\u20131398.","journal-title":"Blood"},{"key":"BFleu2016283_CR39","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1038\/bcj.2014.84","volume":"4","author":"A Pardanani","year":"2014","unstructured":"Pardanani A, Tefferi A . Definition and management of ruxolitinib treatment failure in myelofibrosis. Blood Cancer J 2014; 4: e268.","journal-title":"Blood Cancer J"},{"key":"BFleu2016283_CR40","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kroger","year":"2015","unstructured":"Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by EBMT\/ELN international working group. Leukemia 2015; 29: 2126\u20132133.","journal-title":"Leukemia"},{"key":"BFleu2016283_CR41","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.3109\/10428194.2013.879127","volume":"55","author":"J Mehta","year":"2014","unstructured":"Mehta J, Wang H, Fryzek JP, Iqbal SU, Mesa R . Health resource utilization and cost associated with myeloproliferative neoplasms in a large United States health plan. Leuk Lymphoma 2014; 55: 2368\u20132374.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2016283_CR42","doi-asserted-by":"crossref","unstructured":"Ouagari K, Knight CJ, Mendelson ET . Cost-effectiveness of ruxolitinib versus best-available therapy for medical treatment of myelofibrosis: Canadian societal perspective. Am Soc Hematol Meeting 2012; abstract 4255.","DOI":"10.1182\/blood.V120.21.4255.4255"},{"key":"BFleu2016283_CR43","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1200\/JCO.2012.42.0489","volume":"30","author":"DA Loblaw","year":"2012","unstructured":"Loblaw DA, Prestrud AA, Somerfield MR, Oliver TK, Brouwers MC, Nam RK et al. American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol 2012; 30: 3136\u20133140.","journal-title":"J Clin Oncol"},{"key":"BFleu2016283_CR44","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A . A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703\u20131708.","journal-title":"Blood"},{"key":"BFleu2016283_CR45","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895\u20132901.","journal-title":"Blood"},{"key":"BFleu2016283_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","volume":"118","author":"R Scherber","year":"2011","unstructured":"Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011; 118: 401\u2013408.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016283","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016283.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:27:44Z","timestamp":1648744064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,14]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["BFleu2016283"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.283","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,14]]},"assertion":[{"value":"3 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr Barosi participated in speakers\u2019 bureau for Novartis. Dr Kiladjian\u2019s research was funded by Novartis and AOP Orphan; he also participated in speakers\u2019 bureau for Novartis and AOP Orphan. Dr Passamonti participated in speakers\u2019 bureau for Novartis. Dr Griesshammer received travel reimbursement from Novartis and Shire, participated in speakers\u2019 bureaus for Baxalta, AOP Orphan, Novartis and Shire and received honoraria from Baxalta, AOP Orphan, Novartis and Shire. Dr Vannucchi participated in advisory boards and speakers\u2019 bureaus for Novartis. Dr Kr\u00f6eger received honorarium and research funding from Novartis. Dr McMullin received speaker fee from Novartis and Shire. Dr Harrison received research support from Novartis and honoraria from Baxalta, Novartis, Sanofi and Shire; she joined speakers\u2019 bureaus for Baxalta, Incyte, CTI, Novartis, Sanofi and Shire. Dr Barbui received research grants and speaker fees from Novartis. Dr Marchetti\u2019s research was funded by Janssen, Shire and Celgene; she received travel reimbursements from Janssen, Baxalta, Celgene and Shire and consultant or speaker fees from Gilead and Celgene. Dr Cervantes was a member of advisory boards for Novartis, Baxalta and AOP; he also joined speakers\u2019 bureaus for Novartis, Baxalta and AOP. Dr Birgeg\u00e5rd received research funding and speaker fees from Shire.<b>Author contributions<\/b>BT and MM conceived the project. All the authors contributed to the discussion on the PICOs and approved final recommendations. MM conducted the critical appraisal of the literature, tracked the feedbacks from the panelists and drafted the paper. All the authors revised the manuscript and approved the final version.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}